Acquisition further expands VWRCATALYST Services for Clinical Trial Studies
RADNOR, Pennsylvania, April 7, 2017 /PRNewswire/ -- VWR (NASDAQ: VWR), the leading global independent provider of product and service solutions to laboratory and production customers, announced today that it has acquired MESM Ltd., a provider of laboratory and medical equipment and ancillary supplies to clinical trials worldwide. Widely respected by customers for its ability to source and supply both standard and non-standard products, MESM's exceptional service levels consistently meet customer needs in large complex global studies where time is critical and equipment supply is key.
"MESM is recognized and valued by many of the world's largest pharmaceutical customers and contract research organizations, including a number of existing VWR customers who currently procure our clinical trial and biorepository services," said Manuel Brocke-Benz, President and CEO of VWR. "Their focus on equipment supply and excellence in supply chain further complements VWR's growing service offering as a part of VWRCATALYST, allowing us to better serve our customers in achieving their goals by providing end-to-end product and supply chain solutions."
Founded in 2007, MESM is headquartered in Chorley, UK and operates a second facility in Lakeland, Florida. MESM is ISO9001 certified and is focused exclusively on supporting clinical trials in over 80 countries. Services include equipment sourcing, technical advice and product training, logistics services including import/export compliance, pre-shipment configuration and calibration, in-study equipment servicing and technical support and end-of-study equipment reporting, decommissioning and removal.
Financial details of this acquisition remain confidential.
About VWR
VWR(NASDAQ:VWR), headquartered inRadnor,Pennsylvania, is the leading global independent provider of product and service solutions to laboratory and production customers. With sales in excess of$4.5billionin 2016, VWR enables science for customers in the pharmaceutical, biotechnology, industrial, education, government and healthcare industries. With more than 160 years of experience, VWR has cultivated a value proposition delivering product choice, operational excellence and differentiated services to improve our customers' productivity from research to production. VWR's differentiated services provide innovative, flexible and customized solutions from scientific research services to custom-manufactured chemical blends. Our dedicated team of more than 10,200 associates is focused on supporting scientists, medical professionals and production engineers to achieve their goals.
For more information on VWR, please visitwww.vwr.com.
Media Contact:
Valerie Collado
Director, Corporate Communications
VWR International, LLC
484.885.9338
Valerie_collado@vwr.com
Investor Contact:
John Sweeney, CFA
VP, Investor Relations
VWR Corporation
Phone: +610.386.1483
ir@vwr.com
Logo - https://mma.prnewswire.com/media/95343/vwr_international__llc_logo.jpg
